Literature DB >> 1683797

Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia.

H G Ahuja1, P S Jat, A Foti, M Bar-Eli, M J Cline.   

Abstract

The retinoblastoma-susceptibility (Rb) gene is an antioncogene that is frequently altered in retinoblastomas, sarcomas, and some epithelial tumors. We examined the structure of the Rb gene by Southern blotting in 215 cases of leukemias and lymphomas of diverse phenotype and in 15 leukemic cell lines. In selected cases Rb protein expression was examined with specific monoclonal antibodies. Structural abnormalities of the Rb gene with absent protein expression were frequent in all types of human acute leukemia, but were particularly common (27% incidence) in M4 and M5 myeloid leukemia with monocytic differentiation and in Philadelphia chromosome (Ph1)-positive leukemia of lymphoid phenotype (11% to 29% incidence). Changes in Rb were observed early in the transition to acute leukemia in cases of myelodysplastic syndrome and in the accelerated phase of chronic myelocytic leukemia in transition to blast crisis. In one case, molecular changes in Rb could be correlated with leukemia remission and relapse. We conclude that the Rb antioncogene is commonly involved in the evolution of human acute leukemias, particularly in those of a monocytic phenotype and in lymphoid leukemia in which there is an antecedent alteration of the Ph1 chromosome.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1683797

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Molecular and cellular bases of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Dongguang Li; Shaoguang Li
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

Review 2.  The molecular genetics of hematologic malignancies.

Authors:  A Bagg
Journal:  Clin Diagn Lab Immunol       Date:  1995-05

Review 3.  Risk definition and management strategies in retinoblastoma: current perspectives.

Authors:  Fariba Ghassemi; Alireza Khodabande
Journal:  Clin Ophthalmol       Date:  2015-06-08

4.  Regulatory Network and Prognostic Effect Investigation of PIP4K2A in Leukemia and Solid Cancers.

Authors:  Shouyue Zhang; Zhaozhi Li; Xinyu Yan; Li Bao; Yun Deng; Feier Zeng; Peiqi Wang; Jianhui Zhu; Dandan Yin; Fei Liao; Xueyan Zhou; Duyu Zhang; Xuyang Xia; Hong Wang; Xue Yang; Wanhua Zhang; Hu Gao; Wei Zhang; Li Yang; Qianqian Hou; Heng Xu; Yan Zhang; Yang Shu; Yuelan Wang
Journal:  Front Genet       Date:  2019-01-15       Impact factor: 4.599

Review 5.  Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update.

Authors:  Luana Bavaro; Margherita Martelli; Michele Cavo; Simona Soverini
Journal:  Int J Mol Sci       Date:  2019-12-05       Impact factor: 5.923

Review 6.  Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.

Authors:  Yaoyu Chen; Shaoguang Li
Journal:  Onco Targets Ther       Date:  2014-01-31       Impact factor: 4.147

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.